These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15123372)

  • 1. Monitoring response to antiviral treatment by serum hepatitis C virus core antigen: too early to take shortcuts?
    Mondelli MU
    J Hepatol; 2004 Mar; 40(3):536-8. PubMed ID: 15123372
    [No Abstract]   [Full Text] [Related]  

  • 2. Total HCV core antigen assay. A new marker of HCV viremia and its application during treatment of chronic hepatitis C.
    Lorenzo J; Castro A; Aguilera A; Prieto E; López-Calvo S; Regueiro B; Pedreira J
    J Virol Methods; 2004 Sep; 120(2):173-7. PubMed ID: 15288960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Types of human leukocyte antigen and decrease in HCV core antigen in serum for predicting efficacy of interferon-Alpha in patients with chronic hepatitis C: analysis by a prospective study.
    Muto H; Tanaka E; Matsumoto A; Yoshizawa K; Kiyosawa K;
    J Gastroenterol; 2004 Jul; 39(7):674-80. PubMed ID: 15293139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical benefit of HCV core antigen assay in patients receiving interferon and ribavirin combination therapy].
    Higashimoto M; Takahashi M; Jokyu R; Saito H
    Rinsho Byori; 2006 Feb; 54(2):111-5. PubMed ID: 16548229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of core antigen detection in management of hepatitis C: a critical review.
    Seme K; Poljak M; Babic DZ; Mocilnik T; Vince A
    J Clin Virol; 2005 Feb; 32(2):92-101. PubMed ID: 15653411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clearance duration as a predictor of sustained viral response in patients with chronic hepatitis C virus genotype 1.
    Shenoy M; Levin J; Said A; Striker R
    J Infect Dis; 2005 Jun; 191(11):1993-5; 1995-6. PubMed ID: 15871137
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antigen and viral load].
    Lunel F; Veillon P
    Transfus Clin Biol; 2003 Apr; 10(2):74-7. PubMed ID: 12763148
    [No Abstract]   [Full Text] [Related]  

  • 8. Clearance of HCV RNA in peripheral blood mononuclear cell as a predictor of response to antiviral therapy in patients with chronic hepatitis C.
    Xu DZ; Xie Y; Li ZQ
    Hepatobiliary Pancreat Dis Int; 2005 Nov; 4(4):550-3. PubMed ID: 16286260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: predicting response in hepatitis C virus therapy.
    Mihm U; Herrmann E; Sarrazin C; Zeuzem S
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1043-54. PubMed ID: 16611264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
    Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
    J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological relapse in chronic hepatitis C.
    Poordad FF; Flamm SL
    Antivir Ther; 2009; 14(3):303-13. PubMed ID: 19474464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus. Preface.
    Reddy KR; Kaplan DE
    Clin Liver Dis; 2008 Aug; 12(3):xiii-xiv. PubMed ID: 18625424
    [No Abstract]   [Full Text] [Related]  

  • 13. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribavirin in chronic hepatitis C: past and future.
    Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
    [No Abstract]   [Full Text] [Related]  

  • 15. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment.
    Gopal K; Johnson TC; Gopal S; Walfish A; Bang CT; Suwandhi P; Pena-Sahdala HN; Clain DJ; Bodenheimer HC; Min AD
    Hepatology; 2006 Aug; 44(2):335-40. PubMed ID: 16871569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiles of HCV core protein and viremia in chronic hepatitis C: possible protective role of core antigen in liver damage.
    Carabaich A; Ruvoletto M; Bernardinello E; Tono N; Cavalletto L; Chemello L; Gatta A; Pontisso P
    J Med Virol; 2005 May; 76(1):55-60. PubMed ID: 15778969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy.
    Januszkiewicz-Lewandowska D; Wysocki J; Pernak M; Nowicka K; Zawada M; Rembowska J; Lewandowski K; Mańkowski P; Nowak J
    Jpn J Infect Dis; 2007 Feb; 60(1):29-32. PubMed ID: 17314422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid virologic response: a new milestone in the management of chronic hepatitis C.
    Poordad F; Reddy KR; Martin P
    Clin Infect Dis; 2008 Jan; 46(1):78-84. PubMed ID: 18171217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of chronic hepatitis C and molecular biology tests].
    Córdoba Cortijo J; Molina Moreno JM
    Rev Esp Quimioter; 2005 Sep; 18(3):207-9. PubMed ID: 16369661
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical outcome to interferon therapy in chronic hepatitis C: insights from mechanistic studies.
    Beard MR
    Antivir Ther; 2004 Oct; 9(5):637-9. PubMed ID: 15535401
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.